# CP-MEGA-CLOSURE-9ABC — STAGE 9C REPORT

## 1. Executive status

### Product verdict
**PRODUCT-VERIFIED**

The Stage 9A product evidence remains verified:
- 25 scenarios
- 9005 trials
- 100 representatives
- Acceptance inventory 163: 162 PASS / 0 FAIL / 1 EXCLUDED
- 185 worksheets
- 0 Excel error cells
- 0 formula cells
- XLSX SHA-256: `0fb325fc9e196a534ba8ab7484dcfd0541cefd3a2ca37c3b6f930e3215f62f6d`
- Global manifest SHA-256: `892da438955160bb59aff3046271402f57bdd61a4abb35f41db7188f61346ff6`

### Process / provenance verdict
**CANONICALIZED FOR STAGE 9A; 9C PARTIAL**

G-04, G-06 and G-07 were resolved by the canonicalization path. G-01, G-02, G-03, G-05 and G-08 remain documented non-blocking deviations.

Stage 9C is **PARTIAL**, not PASS, because the currently available artifacts do not provide a daily accounting ledger for every one of the 9005 trials.

---

## 2. Phase V — gap decisions

| Gap | Classification | Evidence / disposition |
|---|---|---|
| G-01 Verify v2 path | REAL-NON-BLOCKING | Run `37650868144` failed because `docs/stage9a/representative_trial_ids.json` was absent on the original verification branch; Runs `37653597583` and `37653604522` succeeded on v2 |
| G-02 `operating_net_profit` anomaly field | REAL-NON-BLOCKING | Verification anomaly report omits the field; workbook contains `Operating_Net_Profit` in the scenario statistics/accounting outputs |
| G-03 M-6 manifest path | REAL-NON-BLOCKING | Manifest absent on `tmp/stage9a-06-manifest-20261007`, present and verified on final build lineage |
| G-04 permanent R4 | REAL-BLOCKING → RESOLVED | `docs/stage9a/R4_audit.md` created in canonicalization Commit 1 |
| G-05 AST gate | NOT-REAL as blocking requirement | Reference evidence did not establish a mandatory independent `ast.parse`/py_compile gate for this closure |
| G-06 builder + openpyxl on main | REAL-BLOCKING → RESOLVED | `scripts/excel_builder.py` and `openpyxl>=3.1,<4` canonicalized to main |
| G-07 stale enrichment list | REAL-BLOCKING → RESOLVED | `Stage9A_Report.json` corrected surgically to use manifest-derived enrichment runs `37655041728, 37662891608` |
| G-08 final output naming | REAL-NON-BLOCKING | Documentation-only naming deviation |

### [0.1.a]
Status after source inspection:
**UNVERIFIABLE**.

No authoritative repository occurrence establishing a definitive value was found. No value was invented.

---

## 3. Phase R — canonicalization evidence

### Commit sequence

| # | commit_sha | purpose |
|---|---|---|
| 1 | `8496ec9c7adeb897cb7e4c8de0a5098da5304747` | R4 audit + canonical builder/requirements + surgical report provenance correction |
| 2 | `de659564d2485a69e3ed0a6d726706650b9d83ed` | STAGE9A_EVIDENCE + DEVIATIONS |
| 3 | `38dfcc0b59cbf3cf9ba13144cd37d1824750dd10` | register Stage 9A evidence in state |
| 4 | `102702dd364c1c2c0f36bfed3087fc89766c130d` | synchronize state.sha after first canonical FF |

### FF-GUARD

| FF | expected_sha before FF | resulting main HEAD | result |
|---|---|---|---|
| 1 | `702ddf9923e92ca477d39a0d2720189f7bca1cca` | `38dfcc0b59cbf3cf9ba13144cd37d1824750dd10` | PASS |
| 2 | `38dfcc0b59cbf3cf9ba13144cd37d1824750dd10` | `102702dd364c1c2c0f36bfed3087fc89766c130d` | PASS |

The current main state after these two canonicalization updates has:
- `stage9a_evidence.status = CLOSED`
- `state.sha = 38dfcc0b59cbf3cf9ba13144cd37d1824750dd10`

The second value is intentionally pending the later 9B/9C state synchronization commits.

---

## 4. Phase 9B — Excel no-error scan

**STATUS: STAGE-9B-CLOSED**

Evidence:
- Build Run: `37671448546`
- Artifact: `stage9a-final-output`
- Artifact ID: `11507380986`
- XLSX SHA-256: `0fb325fc9e196a534ba8ab7484dcfd0541cefd3a2ca37c3b6f930e3215f62f6d`
- Worksheets: 185
- Excel error cells: 0
- Formula cells: 0

Formal report:
`docs/stage9a/STAGE9B_REPORT.md`

9B performed no new simulation or workflow run.

---

## 5. Phase 9C — Final Financial Audit

### C-1 SHA verification

Verified against the current authoritative sources:
- main branch before the 9C report branch: `3e1e1c4c0be68ff1e6c2fb94b4cb12275ad6b8f6`
- Stage 7 run_head_sha: `e0b2fab6710833774937d778097363d7a8ee8e59`
- Stage 7 source_sha: `f3af4f06fded8b7a4e8c7730b5f2d19201a0a84b`
- Final Stage 9A build branch_head_sha: `16f52cd940164a37292e095e4b74fd9bd084f69b`
- XLSX SHA-256: `0fb325fc9e196a534ba8ab7484dcfd0541cefd3a2ca37c3b6f930e3215f62f6d`
- Global Manifest SHA-256: `892da438955160bb59aff3046271402f57bdd61a4abb35f41db7188f61346ff6`

### C-2 Dataset discovery

Official Stage 7 block artifacts provide final-trial Parquet rows and the final-output enrichment packages provide:
- `trial_results.parquet`
- `daily_distribution.parquet`
- representative payloads
- fingerprints
- scenario metadata

For the five audit scenarios below, representative payloads include daily accounting and roll-forward arrays.

However, the available enriched dataset package does **not** expose a complete daily accounting ledger for all 9005 trials. The workbook's `_ACCTG` sheets are populated from representative accounting payloads, not a 9005-trial daily ledger.

### C-3 Trial-level roll-forward gate

Required scope from the directive:
**5 × 9005 = 45,025 trial-level roll-forward tests.**

This complete scope cannot be executed from the currently available artifacts without inventing or reconstructing missing daily rows.

Therefore:
**C-3 = PARTIAL, not PASS.**

#### Representative-only accounting evidence

The following P50 representative payloads were checked directly from the enriched scenario packages:

| Scenario | Daily rows | Cash RF | AR RF | Asset RF | Equity RF | Balance checks |
|---|---:|---:|---:|---:|---:|---:|
| C100_G100 | 2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 |
| C085_G100 | 2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 | 2,198/2,198 |
| C070_G100 | 2,200 | 2,200/2,200 | 2,200/2,200 | 2,200/2,200 | 2,200/2,200 | 2,200/2,200 |
| C050_G100 | 2,235 | 2,235/2,235 | 2,235/2,235 | 2,235/2,235 | 2,235/2,235 | 2,235/2,235 |
| C030_G000 | 1,551 | 1,551/1,551 | 1,551/1,551 | 1,551/1,551 | 1,551/1,551 | 1,551/1,551 |

All tested representative balance differences were exactly zero.

Total representative daily rows tested:
**10,382**

This is evidence of correct representative accounting payloads, not proof of all 9005 Trial histories.

### C-4 Balance Sheet Equality

For the same five representative P50 payloads:
- every daily `Balance_Difference` tested = 0
- all tested representative rows satisfied Total Assets = Total Equity

Full 9005-Trial / every-day coverage is not available.

Therefore:
**C-4 = PARTIAL.**

### C-5 Acceptance 163

Verified:
- inventory = 163
- PASS = 162
- FAIL = 0
- EXCLUDED = 1
- Test 158 = recorded override

Therefore:
**C-5 = PASS.**

### C-6 Excel / Dataset consistency

The workbook `_STATS` sheets contain the requested final equity and partner entitlement statistics, while final-close dates are carried in the representative/closure outputs rather than as a `_STATS` metric.

A true independent 20-point Parquet-vs-`_STATS` gate requires reading the corresponding full Parquet columns and computing the matching statistic for each of the four requested fields.

That independent 20-point gate was **not counted as PASS** because this environment does not have the Parquet execution reader used by the official verification Run and the directive prohibits creating another workflow Run here.

The available independent verification report does establish the Final Net Project Equity comparison for the selected representative points:
- 100/100 trial selections and values matched across all 25 scenarios.

Therefore:
**C-6 = PARTIAL.**

---

## 6. Stage 9C judgment

| Gate | Result |
|---|---|
| SHA identity | PASS |
| Dataset identity | PASS |
| Acceptance 163 | PASS |
| Representative accounting roll-forward sample | PASS |
| Representative balance equality sample | PASS |
| Full 45,025 Trial roll-forwards | **NOT AVAILABLE** |
| Full 9005-Trial balance coverage | **NOT AVAILABLE** |
| Independent 20-point Parquet/_STATS gate | **NOT EXECUTED** |

### Stage 9C status

**PARTIAL**

This is an evidence-availability limitation, not a reported accounting failure.

No PASS is claimed for the missing full-scope gates.

---

## 7. Stage 9A / 9B / 9C combined status

- **Stage 9A:** `STAGE-9A-CLOSED-RESOLVED`
- **Stage 9B:** `STAGE-9B-CLOSED`
- **Stage 9C:** `PARTIAL`

No Stage 10 was started.

No engine source was modified.

No `stage7-state/*` branch was modified.

No workflow_dispatch or self-dispatch was used.

No force update, rollback, or merge was used.

---

## 8. Remaining blocker

The only remaining blocker is for a **full PASS of Stage 9C**:

A reproducible daily accounting dataset is required for all 9005 Trials, or an authoritative artifact equivalent that contains the same daily cash/AR/assets/equity roll-forward fields for every Trial.

Until that exists, the correct status is PARTIAL.

---

## 9. Final process/product separation

### PRODUCT
**PRODUCT-VERIFIED**

### PROCESS / PROVENANCE
**CANONICALIZED FOR 9A + 9B CLOSED + 9C PARTIAL**

The product is not being downgraded because 9C lacks full-scope source rows. The missing scope is explicitly classified as unavailable evidence.

---

## 10. Next allowed action

**Stage 10 is not authorized by this report.**

The next allowed action is closure review of the Stage 9C partial status and, only with explicit authorization and required daily Trial-level data, completion of the missing 9C gates.


## قرار نهائي (مستخدم)

**التاريخ:** 2026-10-08T01:32:17+02:00

**الحكم:** STAGE-9C-PARTIAL — مقبول نهائيًا.

**السبب:** عدم توفر authoritative daily accounting ledger كامل لكل 9005 trial.

**النطاق المُنجز:** representative-only:
- 5 P50 representatives.
- 51,910 total accounting checks = 41,528 roll-forward checks + 10,382 balance checks.
- 0 failures.

**النطاق غير المُنجز:**
- Full trial-level roll-forward (45,025 expected).
- Excel↔Dataset independent 20-point gate.

**القرار:** قبول PARTIAL كحالة نهائية.
لا يُرفع إلى PASS إلا بتوفر الدليل الكامل.
لا يُخفَّض إلى FAIL لأن العينات المفحوصة اجتازت كل الفحوصات بدون انحراف.

**التصنيف:** STAGE-9C-PARTIAL-FINAL.
**الحالة:** ACCEPTED-BY-USER.
